Weekly Research Analysts’ Ratings Updates for Ardelyx (ARDX)

by · The Markets Daily

Several brokerages have updated their recommendations and price targets on shares of Ardelyx (NASDAQ: ARDX) in the last few weeks:

  • 1/21/2026 – Ardelyx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 1/21/2026 – Ardelyx had its price target raised by analysts at Wedbush from $16.00 to $19.00. They now have an “outperform” rating on the stock.
  • 1/9/2026 – Ardelyx had its price target raised by analysts at Citigroup Inc. from $11.00 to $14.00. They now have a “buy” rating on the stock.
  • 1/9/2026 – Ardelyx had its price target raised by analysts at BTIG Research from $14.00 to $17.00. They now have a “buy” rating on the stock.
  • 1/8/2026 – Ardelyx was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating. They now have a $16.00 price target on the stock, up previously from $10.00.
  • 1/8/2026 – Ardelyx had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $19.00 price target on the stock.
  • 11/25/2025 – Ardelyx was downgraded by analysts at Wedbush from an “outperform” rating to a “hold” rating.
  • 11/25/2025 – Ardelyx had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..

Insiders Place Their Bets

In other news, insider Laura A. Williams sold 50,000 shares of Ardelyx stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $6.98, for a total value of $349,000.00. Following the sale, the insider directly owned 361,563 shares of the company’s stock, valued at approximately $2,523,709.74. The trade was a 12.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 46,887 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $5.54, for a total value of $259,753.98. Following the transaction, the chief executive officer directly owned 1,455,363 shares of the company’s stock, valued at approximately $8,062,711.02. The trade was a 3.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 114,868 shares of company stock valued at $708,369. 4.80% of the stock is owned by company insiders.

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

Featured Stories